ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2480

Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis

SA Bergstra1, CF Allaart1, T Stijnen2 and RBM Landewé3,4, 1Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 2Department of Medical Statistics, LUMC, Leiden, Netherlands, Leiden, Netherlands, 3Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, 4Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: combination therapies, Early Rheumatoid Arthritis, meta-analysis and methotrexate (MTX)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Recently, there has been a trend to start methotrexate (MTX) in higher doses, either as monotherapy or in combination with other drugs in rheumatoid arthritis (RA) trials –and likely also in daily practice. It is unclear whether higher initial doses are associated with better short term clinical responses, especially in combination therapy with other effective disease modifying anti-rheumatic drugs (DMARDs). We investigated the short term relationship with early clinical response of various doses of MTX in monotherapy and combination therapy in DMARD naive early RA patients.

Methods: A systematic literature search was performed, including early, DMARD naive RA patients, treated with MTX, showing disease activity results within 3 to 6 months follow-up. Cohen’s effect sizes (ratio of mean change in score and baseline SD, with negative scores indicating improvement) were calculated for the health assessment questionnaire (HAQ), erythrocyte sedimentation rate/c-reactive protein (ESR/CRP) and/or DAS/DAS28 in 4 treatment groups: MTX monotherapy, and MTX in combination with synthetic (cs)DMARDs, or with biologic (b)DMARDs or with oral glucocorticoids. Multivariate random-effects meta-regression analyses were performed for each outcome, with treatment group as predictor corrected for standardized baseline disease activity and month of assessment.

Results: Out of 2567 articles and 417 meeting abstracts, 31 studies including 5589 patients were extracted. The meta-regression (table 1) did not show any indication for  higher effectiveness of increasing MTX doses in monotherapy. In combination with glucorticoids a higher MTX dose was statistically significantly associated with higher HAQ (β=0.012, 95% CI 0.00070;0.023), but not with DAS/DAS28 or ESR/CRP. In combination with bDMARDs a higher MTX dose was statistically significantly associated with higher HAQ (β=0.042, 95% CI 0.012;0.073) and DAS/DAS28 (β=0.033, 95% CI 0.0070;0.059). These effect sizes were too small to indicate clinical relevant effects on disease activity/functional ability. There were too few treatment groups using MTX in combination with csDMARDs to evaluate in the meta-regression.

Conclusion: In DMARD naive early RA patients, a higher initial dose of MTX either as monotherapy or in combination with a bDMARD or glucocorticoid was not associated with better clinical responses within 3 to 6 months of treatment start. Initial combination therapies with a bDMARD or glucocorticoid show higher effect sizes than initial monotherapy. The results suggest that such initial combination therapies give better short term clinical outcomes, but that the benefits to be expected from higher in stead of lower doses of MTX is negligible.  

Table 1: Meta-regression on the effect of methotrexate-dose on HAQ (n=23), DAS/DAS28 (n=25) and ESR/CRP (n=21).
HAQ   β SE P 95% CI
MTX monotherapy MTX dose (mg) -0.008 0.014 0.584 -0.035; 0.020
Month of assessmenta -0.0021 0.084 0.980 -0.17; 0.16
Baseline HAQ -0.11 0.19 0.570 -0.49; 0.27
constant -0.29 0.49 0.556 -1.26; 0.68
Combination therapy with glucocorticoids MTX dose (mg) 0.012 0.0058 0.037 0.00070; 0.023
Month of assessmenta -0.033 0.038 0.380 -0.11; 0.041
Baseline HAQ -0.42 0.11 <0.001 -0.63; -0.21
constant -0.33 0.23 0.151 -0.79; 0.12
Combination therapy with bDMARDs MTX dose (mg) 0.042 0.016 0.007 0.012; 0.073
Month of assessmenta 0.094 0.12 0.430 -0.14; 0.33
Baseline HAQ -0.71 0.60 0.240 -1.88; 0.47
constant -0.97 0.73 0.186 -2.41; 0.47
DAS/DAS28   β SE P 95% CI
MTX monotherapy MTX dose (mg) -0.042 0.031 0.170 -0.10; 0.018
Month of assessmenta -0.064 0.21 0.766 -0.48; 0.35
Baseline DAS/DAS28 -0.62 0.077 <0.001 -0.78; -0.47
constant 0.82 1.04 0.426 -1.21; 2.86
Combination therapy with glucocorticoids MTX dose (mg) -0.0010 0.018 0.954 -0.035; 0.033
Month of assessmenta -0.046 0.11 0.672 -0.26; 0.17
Baseline DAS/DAS28 -0.91 0.16 <0.001 -1.23; -0.60
constant 0.10 0.73 0.885 -1.32; 1.53
Combination therapy with bDMARDs MTX dose (mg) 0.033 0.013 0.013 0.0070; 0.059
Month of assessmenta 0.10 0.15 0.503 -0.19; 0.39
Baseline DAS/DAS28 -1.03 0.18 <0.001 -1.38; -0.69
constant -0.14 0.64 0.827 -1.39; 1.11
ESR/CRP   β SE P 95% CI
MTX monotherapy MTX dose (mg) -0.043 0.048 0.372 -0.14; 0.052
Month of assessmenta -0.20 0.37 0.593 -0.92; 0.53
Baseline ESR/CRP -0.81 0.75 0.281 -2.29; 0.66
constant 1.47 1.29 0.252 -1.04; 4.01
Combination therapy with glucocorticoids MTX dose (mg) 0.00074 0.092 0.994 -0.18; 0.18
Month of assessmenta -0.061 0.65 0.926 -1.34; 1.22
Baseline  ESR/CRP -0.83 4.33 0.848 -9.32; 7.66
constant -0.32 3.92 0.934 -8.01; 7.37
Combination therapy with bDMARDs MTX dose (mg) 0.037 0.24 0.880 -0.44; 0.52
Month of assessmenta -0.25 1.23 0.841 -2.66; 2.17
Baseline ESR/CRP 0.21 9.37 0.982 -18.15; 18.57
constant -0.93 6.37 0.884 -14.18; 12.41
aNumber of months after treatment start

 


Disclosure: S. Bergstra, None; C. Allaart, None; T. Stijnen, None; R. Landewé, Abbott, Amgen, Centocor, Novartis, Pfizer, Rhoche, Schering-Plough, UCB, Wyeth., 2,Robert Landewé is director of Rheumatology Consultancy BV, which is a registered company under Dutch law., 4,Abbott/AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol Myers Squibb, Celgene, Janssen (formerly Centocor), Galapagos, Glaxo-Smith-Kline, Novartis, Novo-Nordisk, Merck, Pfizer, Rhoche, Schering-Plough, TiGenix, UCB, Wyeth., 5,Abbott/AbbVie, Amgen, Bristol Myers Squibb, Janssen (formerly Centocor), Merck, Pfizer, Rhoche, Schering-Plough, UCB, Wyeth., 9.

To cite this abstract in AMA style:

Bergstra S, Allaart C, Stijnen T, Landewé R. Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/dose-related-short-term-clinical-response-to-initial-treatment-with-methotrexate-in-mono-and-combination-therapy-in-early-rheumatoid-arthritis-patients-a-meta-regression-analysis/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dose-related-short-term-clinical-response-to-initial-treatment-with-methotrexate-in-mono-and-combination-therapy-in-early-rheumatoid-arthritis-patients-a-meta-regression-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.